ICU Medical Director Reports 1,200-Share Purchase on 08/27/2025
Rhea-AI Filing Summary
David C. Greenberg, a director of ICU Medical, Inc. (ICUI), reported open-market purchases on 08/27/2025. The Form 4 shows two non-derivative purchases: 602 shares at a weighted-average price of $126.1428, bringing his direct beneficial ownership to 7,362 shares, and 598 shares at a weighted-average price of $126.6895, bringing his direct beneficial ownership to 7,960 shares. The filing also discloses 500 shares held indirectly by a trust. The purchases were executed in multiple transactions within the disclosed price ranges; the filer offers to provide detailed per-transaction pricing on request.
Positive
- Director purchase disclosed: David C. Greenberg bought 1,200 shares on 08/27/2025, signaling insider buying.
- Transparent reporting: Weighted-average prices and price ranges are disclosed with a commitment to provide per-trade details on request.
Negative
- None.
Insights
TL;DR: A company director made modest open-market buys totaling 1,200 shares at ~ $126–127, increasing direct ownership.
These purchases represent routine insider buying by a director and may signal confidence, though the sizes (602 and 598 shares) are small relative to typical institutional levels. The Form 4 provides weighted-average prices and discloses that trades occurred across multiple executions. No options or derivative transactions were reported. Absent additional context on total share count or recent trading patterns, this is a limited, liquidity-scale insider purchase rather than a transformative ownership change.
TL;DR: Reporting is compliant and transparent; multiple-execution prices are disclosed with offer to provide detail.
The filing properly identifies the reporting person as a director, shows individual filing status, and includes an attorney-in-fact signature. The explanatory footnotes transparently state that reported prices are weighted averages across ranges and offer to furnish per-trade details upon request, which supports governance transparency. No departures from normal Section 16 reporting practices are evident.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 602 | $126.1428 | $76K |
| Purchase | Common Stock | 598 | $126.6895 | $76K |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $125.52 to $126.48, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4. The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $126.55 to $127.14, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.
